Human CTSD (Cathepsin D) ELISA Kit (E-EL-H6269)
Add to cart
For research use only.
Product Summary
| Sensitivity | 0.94 ng/mL |
| Detection Range | 1.56-100 ng/mL |
| Sample Volume | 100 μL |
| Total Assay Time | 3 h 30 min |
| Reactivity | Human |
| Specificity | This kit recognizes CTSD in samples.No significant cross-reactivity or interference between CTSD and analogues was observed. |
| Recovery | 80%-120% |
| Sample Type | serum,plasma,other biological fluids |
| Detection Method | Colorimetric method, ELISA, Sandwich |
| Assay Type | Sandwich-ELISA |
| Size | 96T / 48T / 24T / 96T*5 / 96T*10 |
| Storage | 2-8℃ |
| Expiration Date | 12 months |
Performance
| Typical data |
The following data was generated by the Quality Control Department, under controlled laboratory conditions (ambient temperature: 18-25 °C, relative humidity: 35-75%) using standardized procedures (TMB reaction at 37 °C in the dark for 15 minutes, followed by termination and OD measurement). These values are provided for reference only.
Actual results may vary due to differences in laboratory conditions, operator technique, and equipment. Users are required to generate a standard curve using their own experimental data.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Precision |
Intra-assay Precision (Within-run Precision): Three samples representing low, mid, and high concentrations of Human CTSD were tested 20 times on a single plate.
Inter-assay Precision (Between-run Precision): Three samples representing low, mid, and high concentrations of Human CTSD were tested on three separate plates, with 20 replicates per plate, to assess variability among assays.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Recovery |
The recovery of Human CTSD was evaluated by spiking samples at low, mid, and high concentrations across the assay range in various sample matrices.
The assay performance was assessed by comparing the measured concentrations to the expected spiked amounts to determine the percent recovery.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Linearity |
Linearity of the assay was evaluated by spiking samples with high concentrations of Human CTSD and performing serial dilutions using Standard & Sample Diluent to produce concentrations spanning the assay's dynamic range.
The measured values were then compared to the expected concentrations to assess the linearity of response.
|
|||||||||||||||||||||||||||||||||||||||||||||
| Stability |
Each kit batch is subjected to accelerated stability testing and real-time stability monitoring. Sample performance is evaluated after storage at 37 °C for 10 days to assess the impact of elevated temperature on assay reliability and reagent integrity.
|
|||||||||||||||||||||||||||||||||||||||||||||
Test Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Rat ApoH . Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Rat ApoH and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Rat ApoH , biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Rat ApoH . You can calculate the concentration of Rat ApoH in the samples by comparing the OD of the samples to the standard curve.
Background
Cathepsin D (CTSD) is a ubiquitously expressed lysosomal aspartic protease of the pepsin family. It is synthesized as a 412-amino-acid preproenzyme that loses its signal peptide in the endoplasmic reticulum, receives mannose-6-phosphate tags in the Golgi apparatus and is targeted to endosomes and lysosomes, where the propeptide is removed and the single chain is cleaved into a mature two-chain form of approximately 34 kDa and 14 kDa. The active site contains two aspartate residues and works optimally at acidic pH, which restricts proteolysis to the endosomal-lysosomal compartment and to the acidic extracellular space of tumours. Cathepsin D is abundant in macrophages, hepatocytes, neurons and ductal epithelial cells, and its expression is induced by estrogens and growth factors.
Within the lysosome, cathepsin D participates in bulk degradation of endocytosed and autophagocytosed proteins and in the processing of substrates that include prolactin, insulin-like growth factor binding proteins, antigenic peptides for MHC class II presentation and the amyloid precursor protein. Through these activities the protease contributes to protein turnover, antigen presentation, hormone and growth factor bioavailability, apoptosis and neuronal homeostasis. When released into the cytosol it can cleave Bid and amplify apoptotic signalling, and when secreted by tumour cells it degrades extracellular matrix and liberates growth factors that favour invasion and angiogenesis.
Altered cathepsin D activity underlies several human diseases. Loss-of-function mutations cause neuronal ceroid lipofuscinosis type 10 (CLN10), a congenital neurodegenerative lysosomal storage disorder with severe brain atrophy and epilepsy. In oncology, cathepsin D is overexpressed in a large proportion of breast carcinomas, where it is regulated by estrogen and has been reported as an independent marker of poor prognosis, and elevated expression or secretion has also been described in ovarian, endometrial, prostate, colorectal and lung cancer and in melanoma, in which it promotes proliferation, invasion and resistance to apoptosis. Cathepsin D is further implicated in atherosclerosis and in cartilage and matrix degradation in osteoarthritis and rheumatoid arthritis, and its activity contributes to amyloid-beta handling in Alzheimer disease. Quantification of cathepsin D is therefore applied to studies of lysosomal function, tumour biology and prognosis, and neurodegeneration.
| Gene ID | 1509 |
| Uniport ID | P07339 |
| Research Area | Cancer |
-
IF:{{item.impact}}
Journal:{{item.journal}} ({{item.year}})
DOI:{{item.doi}}Reactivity:{{item.species}}
Sample Type:{{item.sample_type}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
No files available. Please enter the correct identification code in the search area to query the relevant documents.
| Title | Status | Valid until | Action | |
|---|---|---|---|---|
| {{v.文件名}} | {{v.status_str}} | {{v.timestamp_str}} | Download | / |
*Note:Please download the relevant files within the validity period. After expiration, file preview and download will not be available on the page.
Resources
Contact with Us
Toll-free: 1-888-852-8623
Tel: 1-832-243-6086
Add:
14780 Memorial Drive, Suite 105, Houston, Texas, 77079, USA

